1196152-38-1

Basic information

• Product Name: 2-BroMo-5-trifluoroMethyl-pyrazine
• Synonyms: 2-BroMo-5-trifluoroMethyl-pyrazine;2-Bromo-5-Trifluorimethylpyrazine;Pyrazine, 2-bromo-5-(trifluoromethyl)-
• CAS NO: 1196152-38-1
• Molecular Formula: C₅H₂BrF₃N₂
• Molecular Weight: 226.9819896
• Mol File: 1196152-38-1.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 189.4±35.0 °C(Predicted)
• Appearance: /
• Density: 1.807±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -4.55±0.10(Predicted)
• CAS DataBase Reference: 2-BroMo-5-trifluoroMethyl-pyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BroMo-5-trifluoroMethyl-pyrazine(1196152-38-1)
• EPA Substance Registry System: 2-BroMo-5-trifluoroMethyl-pyrazine(1196152-38-1)

Safety Data

• Hazardous Substances Data: 1196152-38-1(Hazardous Substances Data)

Usage

General Description

2-Bromo-5-trifluoromethyl-pyrazine is a chemical compound with a molecular formula C5H3BrF3N2. It is a pyrazine derivative with a bromo substituent at the 2 position and a trifluoromethyl group at the 5 position. 2-BroMo-5-trifluoroMethyl-pyrazine is used in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is also used as a building block for the preparation of various heterocyclic compounds. 2-Bromo-5-trifluoromethyl-pyrazine is a versatile intermediate in organic synthesis and has potential applications in the pharmaceutical and agricultural industries.

Upstream product

• 69816-38-2 5-trifluoromethyl-pyrazin-2-ylamine 
• 81290-20-2 (trifluoromethyl)trimethylsilane 
• 622392-04-5 2-bromo-5-iodo-pyrazine 

Downstream Products

• 1621366-99-1 N-(3,4-difluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide 

Relevant articles and documents

Selective GlyT1 inhibitors: Discovery of [4-(3-fluoro-5- trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2, 2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia

The GlyT1 transporter has emerged as a key novel target for the treatment of schizophrenia. Herein, we report on the optimization of the 2-alkoxy-5-methylsulfonebenzoylpiperazine class of GlyT1 inhibitors to improve hERG channel selectivity and brain penetration. This effort culminated in the discovery of compound 10a (RG1678), the first potent and selective GlyT1 inhibitor to have a beneficial effect in schizophrenic patients in a phase II clinical trial.